marked.bio

AKT inhibitor · small molecule

afuresertib

1 active trials, targeting AKT. Not approved for any biomarker on marked.bio yet.

Also known as GSK2110183, LAE002.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
PIK3CA activating mutation 1 2 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of afuresertib.

  1. Laekna 1

Trials

1 of 2 trials shown

  1. Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

    Active, not recruiting Phase 3 Laekna Started 2022Primary completion 2026-10 NCT04851613

    afuresertibfulvestrant FDA EU

    Only patients with PIK3CA/AKT1/PTEN alterations could include.

    PIK3CA activating mutationBreast Cancer